News

Filter

1 to 9 of 36 results

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

16-06-2014

UK pharma major GlaxoSmithKline announced the results from the Phase III PETIT2 study evaluating the…

eltrombopagEuropeGlaxoSmithKlineHealth Medical PharmaHematologyItalyMajorMedicinePharmaceuticalResearchThrombocytopenic purpura

GSK’s eltrombopag performs well in Phase III PETIT2 study

GSK’s eltrombopag performs well in Phase III PETIT2 study

13-06-2014

UK pharma major GlaxoSmithKline has announced positive results from the Phase III PETIT2 study evaluating…

eltrombopagGlaxoSmithKlineOncologyPharmaceuticalResearchThrombocytopenic purpuraUK

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

Ligand narrows loss on rocketing revenue

08-05-2009

Ligand Pharmaceuticals narrowed its loss by 23% year-on-year for the first quarter, on rocketing revenue…

eltrombopagGlaxoSmithKlineGSKPfizerPromactaSchering PloughSchering-PloughWyeth

Ligand gets $500K under GSK accord

31-03-2009

The USA's Ligand Pharmaceuticals has identified a new lead compound for advancement in its alliance with…

eltrombopagGlaxoSmithKlineGSKPromacta

Ligand swings to loss on merger and legal fees

23-02-2009

US firm Ligand Pharmaceuticals has swung to loss, despite higher sales, in the 12 months to December…

eltrombopagGlaxoSmithKlineGSKPromacta

1 to 9 of 36 results

COMPANY SPOTLIGHT

Menarini

Back to top